At NVIDIA GTC Paris, leading healthcare and life sciences companies from Europe are spotlighting their pioneering use of artificial intelligence to confront critical challenges within global health systems. With rising pressures from staff shortages, rapidly aging populations, and escalating costs, organizations across the sector are ramping up efforts in biopharma, digital medicine, and population health. Much of their momentum stems from support by the NVIDIA Inception program, granting startups access to cutting-edge developer tools, advanced training, and connections to venture capital, combining technology enablement with business growth.
Laying solid foundations for data-driven biosciences, London-based Basecamp Research introduced BaseData, now the world’s largest biological dataset built for generative artificial intelligence in life sciences. Sourced from a global network spanning 26 countries, the data trove consists of over 9.8 billion new biological sequences and identifies more than a million previously unknown species, vastly outpacing current public repositories. Through collaborations with NVIDIA, Basecamp leverages the BioNeMo platform and DGX Cloud Lepton to power the training of next-generation biological foundation models, bridging former gaps in diversity, scale, and governance while propelling the growth of generative biology and accelerating drug discovery pipelines.
Transforming how care is delivered, Guy’s and St. Thomas’ NHS Foundation Trust—the UK’s largest—has launched the PATH initiative, joining forces with General Catalyst and startups Hippocratic AI and Sword Health. The integration of advanced artificial intelligence agents into workflows is intended to shorten specialty care waitlists, streamline triage, and personalize outreach. Hippocratic AI’s conversational agents and Sword Health’s AI Care platform automate tasks like patient communication and referral processing, having already provided over 6.5 million artificial intelligence sessions worldwide. The PATH effort actively targets elective care backlogs, aiming to design national-scale solutions that increase access, bolster clinical outcomes, and reshape the healthcare experience across the NHS.
Pangaea Data, operating in London and San Francisco, is closing critical diagnostic gaps by using artificial intelligence to uncover untreated or misdiagnosed patients directly from unstructured medical record data. Utilizing the NVIDIA NeMo Agent toolkit, alongside NVIDIA NIM microservices and large language models, Pangaea’s platform accurately emulates clinician review to detect rare and hard-to-diagnose disease presentations. This technology is now in deployment across health systems in the US, UK, Spain, and Barbados, fueling broader health equity and real-time patient discovery for global public health initiatives.
Meanwhile, NVIDIA’s DGX Cloud Lepton infrastructure is underpinning the scale-up of high-potential European startups with the support of venture firms like Sofinnova. Firms such as Cure51, Sensible Biotechnologies, and Molecular Glue Labs have gained early access, recording major efficiency gains: Cure51 accelerated genomic analyses by 17x and halved costs by utilizing NVIDIA DGX Cloud, while Sensible compressed its mRNA therapeutic optimization timelines from weeks to a single day. These advances illustrate not only the growing influence of sovereign artificial intelligence infrastructure, but also how regional cloud partners and innovation labs are becoming critical enablers of early-stage biotech breakthroughs.
